Written by International Journal of Pharmacology and Clinical Sciences, 2024, 13, 1, 10.
Published: November 2024
Type: Drug Review
Authors: Juman Alsaab
Author(s) affiliations:
Juman Alsaab,
Pharm D, Ministry of Health, Riyadh, SAUDI ARABIA.
Abstract
Regulations: had been registered in the following countries: UnitedStates of America (USA). Registration number (S.A.): Not available. Insurance Drug Formulary (S.A.): Not available. General Information: Registered Company: Ionis Pharmaceuticals and AstraZeneca. Regulatory Status: R.X.Mechanism of Action: Plontersen, an antisense oligonucleotideGa1NAc conjugate, is structurally represented as [insert chemical structure here]. This drug causes degradation of mutant and wild-type transthyretin (TTR) mRNA through binding to the TTR mRNA. Read more…